Why the study?
Does bezafibrate reduce all-cause mortality in patients with coronary artery disease?
Does bezafibrate reduce all-cause mortality in patients with coronary artery disease?
Long-term follow-up of the BIP trial demonstrates that bezafibrate provides a modest long-term mortality benefit in CAD patients, which is particularly pronounced in those with baseline hypertriglyceridemia.
No takes yet. Share an insight, caveat, or question.
Supports bezafibrate for long-term mortality reduction in CAD; extends BIP trial to all-cause survival benefit.
Arbel et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: